
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is in a strong position to capitalize on the growing demand for vaccines with its promising technology and broad pipeline of potential products. Their recent partnerships with top global pharmaceutical companies and expansion into diverse fields such as oncology and infectious diseases only add to their potential for success. Additionally, the positive support from physician groups for the COVID vaccine and the potential for increased uptake of Nuvaxovid due to its better tolerability than mRNA vaccines bodes well for the company's commercial outlook. The risks to the downside for Novavax include failure to develop a successful combo vaccine and potential negative regulatory developments, but overall, the company's strong fundamentals and growing market opportunity make it a favorable investment opportunity.
Bears say
Novavax is a well-established biotechnology company with a promising pipeline of vaccine candidates, however, the recent tolerability data from Sanofi may not be enough to differentiate their product in a crowded COVID-19 vaccine market. The company's reliance on Matrix-M adjuvant and partnerships for value creation may also present potential risks and uncertainties. The declining market share predictions for Nuvaxovid and potential competition in the future may also negatively impact the company's financials and stock performance.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares